Peptide Referee

Eloralintide: research, legal status and who sells it

This page is information, not medical advice. Eloralintide is not approved as a medicine in the markets below unless stated. We don't publish dosing or usage instructions.

Also known as
LY3841136
Category
Investigational long-acting amylin receptor agonist
Evidence level
Early human trials
Price range
$6.00/mg to $15.00/mg, median $7.54/mg across 7 vendors (compare)
Our lab tests
None yet (how testing will work)
WhereStatus
United StatesNo FDA-approved drug contains eloralintide [1].
United KingdomNo UK-licensed medicine containing eloralintide appears in the MHRA products database [2].
European UnionNo medicine containing eloralintide is authorized in the EU, according to EMA's central and Article 57 product data [3][4].
CanadaNo product containing eloralintide appears in Health Canada's Drug Product Database [5].
AustraliaEloralintide is not named in Australia's Poisons Standard (October 2026) [6].
Sport (WADA)Not named on the 2026 Prohibited List; its section S0 bans any pharmacological substance with no current approval for human therapeutic use [7].
 Summaries of official sources, checked —. Rules change; follow the source links. Not legal advice.

We haven't published a full overview of Eloralintide yet. The legal status table and live prices on this page are current.

Eloralintide prices: cheapest listings

The five lowest $/mg listings out of 7. See all Eloralintide prices

Vendor Transparency Product Size Price $/mg vs median Stock Vendor's page
Royal Peptides FDA warning letter, Aug 2026 52/100 Eloralintide (LY3841136) Research Peptide 10 mg $60 $6.00/mg −20% In stock View
Nexaph 45/100* Eloralintide 10mg (10 vials/Kit) 10 mg × 10 $618 $6.18/mg −18% In stock View
Reta One Labs 55/100* Eloralintide 10mg 10 mg $89 $8.90/mg +18% In stock View
Volta Peptides 70/100 Eloralintide 10mg 10 mg $99 $9.90/mg +31% Out of stock View
PS Peptides 22/100* Eloralintide (1 Vial) 10 mg $120 $12.00/mg +59% Out of stock View

Prices come from each vendor's public product feed and were last fetched Oct 15, 2026. They exclude shipping and discounts. $/mg uses the labeled amount, not measured content. A transparency score marked * is based on fewer than six checks; checks we couldn't complete score 0. How we compare prices.

Sources

  1. Drugs@FDA: FDA-Approved Drugs (database searched by active ingredient). U.S. Food and Drug Administration. Accessed Oct 15, 2026
  2. MHRA Products: licensed-medicine search for "eloralintide". Medicines and Healthcare products Regulatory Agency (UK). Accessed Oct 15, 2026
  3. EMA medicines data: centrally authorised human medicines (export of 14 October 2026). European Medicines Agency. Accessed Oct 15, 2026
  4. EMA Article 57 product data: medicines authorised in the EU/EEA (data as of 9 October 2026). European Medicines Agency. Accessed Oct 15, 2026
  5. Drug Product Database online query (searched by active ingredient). Health Canada. Accessed Oct 15, 2026
  6. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327, registered 30 September 2026). Federal Register of Legislation, Australian Government. Accessed Oct 15, 2026
  7. World Anti-Doping Code International Standard: Prohibited List 2026 (in force 1 January 2026). World Anti-Doping Agency. Accessed Oct 15, 2026
  8. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet (2025). Accessed Oct 15, 2026
  9. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Molecular Metabolism (2025). Accessed Oct 15, 2026